Top

Mimi I. Hu, M.D.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine

About Dr. Mimi I. Hu

Dr. Mimi I. Hu graduated from Rice University with a degree in mechanical engineering. She obtained her medical degree from the University of Texas - Houston Health Sciences Center. She completed her residency and endocrine fellowship at the Baylor College of Medicine, where she also served as chief medical resident. After completion of her research fellowship at MD Anderson, she joined the faculty in 2007 in the department of Endocrine Neoplasia and Hormonal Disorders. Dr. Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma (differentiated and medullary), hereditary endocrine neoplasia disorders and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders.

Primary Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Assistant Professor (Joint appointment), Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas

Clinical Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston, Texas

Research Interests

Novel therapeutics for thyroid cancer;
Medullary thyroid cancer;
Bone and mineral metabolism disorders

Clinical Interests

Thyroid carcinoma - differentiated and medullary;
Multiple endocrine neoplasia, Types 1 and 2;
Bone and mineral metabolism disorders;
Parathyroid disorders;
Pituitary tumors;
Endocrine effects of cancer and its therapies

For general clinic information, please visit the Department of Endocrine Neoplasia and Hormonal Disorders' contact information website listed below:

Contact Information

Education & Training

Degree-Granting Education

2000	University of Texas Houston Health Science Center, Houston, Texas, US, MD
1993	Rice University, Houston, Texas, US, BS in Mechanical Engineering

Postgraduate Training

2009-2009	Faculty Development, Heart of Leadership, The University of Texas MD Anderson Cancer Center, Houston, Texas
2005-2008	Clinical Research Curriculum, University of Texas-Houston Medical School, Houston, Texas
2004-2007	Clinical Fellowship, Endocrinology, Baylor College of Medicine, Houston, Texas
2001-2003	Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas
2000-2001	Clinical Internship, Internal Medicine, Baylor College of Medicine, Houston, Texas

Licenses & Certifications

2023	Georgia Medical Board
2023	Oklahoma State Board of Medical Licensure & Supervision
2023	Louisiana Medical Board
2023	Tennessee Board of Medical Examiners
2023	Arizona Medical Board
2023	Alabama Board of Medical Examiners
2023	Washington Medical Commission
2021	Florida Board of Medicine
2006	Endocrinology, Diabetes and Metabolism
2004	Internal Medicine
2002	Texas Medical Board

Experience & Service

Faculty Academic Appointments

Chief Medical Resident, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, 2023 - 2024

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2013 - 2018

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2007 - 2013

Administrative Appointments/Responsibilities

Deputy Department Chair, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - Present

OneConnect SuperUser, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - 2016

Associate Medical Director of Endocrine Center, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - 2021

EHR Provider Officer, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - 2016

Fellowship Program Director, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011 - Present

Director, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011 - 2021

Rotation Site Director, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2008 - 2014

Member, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2008 - Present

Facilitator, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2006 - 2021

Other Professional Positions

Member, Medullary Thyroid Cancer Registry Steering Committee, Houston, Texas, 2018 - Present

Member, Baylor College of Medicine, Houston, Texas, 2008 - 2012

Director, Baylor College of Medicine, Houston, Texas, 2007 - 2010

Facilitator, Baylor College of Medicine, Houston, Texas, 2005 - 2006

Member, Baylor College of Medicine, Houston, Texas, 2003 - 2004

Facilitator, Baylor College of Medicine, Houston, Texas, 2003 - 2004

Buddy for Intern Class, Baylor College of Medicine, Houston, Texas, 2001 - 2002

Mentor, Baylor College of Medicine, Houston, Texas, 2001 - 2003

Tutor for Medical Students, University of Texas Houston Health Sciences Center, Houston, Texas, 1997 - 1998

Research Assistant, University of Texas Houston Medical School, Houston, Texas, 1997 - Present

Research Assistant, Baylor College of Medicine, Houston, Texas, 1995 - 1996

Intramural Institutional Committee Activities

Member, Endocrine Center Shared Governance Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Member, Ascending Senior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

Member, Scientific Review Committee (SRC) #1, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Texas Medical Board Approved Programs Liaison, Graduate Medical Education Executive Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2021

Member, Search Committee for Chair of Head and Neck Surgery Department, The University of Texas MD Anderson Cancer Center, 2017 - 2017

Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2016 - 2019

Member, Search Committee for Section Chief of Head and Neck Endocrine Surgery, The University of Texas MD Anderson Cancer Center, 2016 - 2016

Chair, Clinical Operations Committee in Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2016 - 2020

Member, Department of Endocrine Neoplasia and Hormonal Disorders Executive Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Chair, Clinical Faculty Search Committee for Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Member, Endocrine Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2021

Division Representative, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Clinical Research Committee 3, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Pharmacy & Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2016

Member, Clinical Research Committee 4, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Member, Multidisciplinary Bone Health Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2016

Member, Editorial Board for Department Publications and Website Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2016

Member, Endocrine Center Steering Committee for the Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, 2008 - 2010

Member, Clinical Research Committee 2, The University of Texas MD Anderson Cancer Center, 2008 - 2010

Member, Graduate Medical Education Budget Subcommittee, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2013

Extramural Institutional Committee Activities

Member, IMC Lean Initiative, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Editorial Activities

Section Editor - MEN2 Topics, UpToDate (Endocrinology & Diabetes Content), 2022 - Present

Member, Editorial Board, International Journal of Basic and Clinical Endocrinology, 2020 - 2022

Medical Content Editor, Update Report: Low Bone Density, 2009 - 2011

Honors & Awards

2025	Top 1% Provider in the Nation, ThyCa: Thyroid Cancer Survivors’ Association
2023	ATA's Galton Distinguished Lectureship Award, American Thyroid Association
2023 - 2024	GME Program Director Award, The University of Texas MD Anderson Cancer Center
2022	Nomination for Division of Internal Medicine Excellence in Patient Care
2021	DoIM Distinguished Paper Award for Clinical Research (Jan - Jun 2021 Period), MDACC Division of Internal Medicine
2021	DoIM Distinguished Paper Award for Clinical Research (July - December 2021 Period), MDACC Division of Internal Medicine
2020	Nomination for the Division of Internal Medicine Excellence Award - Excellence in Education
2019 - 2025	Exceptional Woman in Medicine, Castle Connolly
2018	2018 Faculty Excellence in Education & Mentorship Advancement, The University of Texas MD Anderson Cancer Center
2017	Nomination for Department of Education Outstanding GME Program Director Award, The University of Texas MD Anderson Cancer Center
2017 - 2018	Best Doctors in America, Best Doctors
2016 - 2017	Faculty Leadership Academy (Cohort 16), The University of Texas MD Anderson Cancer Center
2015	ENDO 2015 Outstanding Abstract Award and Presidential Poster Competition Finalist, Endocrine Society 97th Annual Meeting
2014	Faculty Educator of the Month - May 2014, MD Anderson Cancer Center
2014 - 2025	Top Doctors in America, Castle Connolly
2011	ENDO 2011 Outstanding Abstract Award and Presidential Poster Competition Finalist, Endocrine Society 93rd Annual Meeting
2011 - 2012	U.S. News Top Doctors, U.S. News and World Report, Castle Connolly Medical Ltd
2009	Heart of Leadership, The University of Texas MD Anderson Cancer Center
2006	Travel Grant Award for Young Investigators, American Thyroid Association 77th Annual Meeting
1999	Alpha Omega Alpha Honor Society
1998	Chinese American Doctors Association of Houston Scholarship
1997 - 2000	Lucy Massenburg Scholarship, University of Texas Houston Health Sciences Center

Professional Memberships

North American Neuroendocrine Tumor Society

2022 - 2023

European Society of Medical Oncology

2020 - 2023

International Thyroid Oncology Group

2019 - Present

ThyCa Medical Advisory Panel

2016 - Present

Harris County Medical Society

2007 - 2023

American Society of Clinical Oncology

2007 - Present

American Society for Bone and Mineral Research

2007 - Present

American Thyroid Association

2006 - Present

Endocrine Society

2006 - Present

American Association of Clinical Endocrinologists

2005 - Present

American College of Physicians

2000 - 2013

Texas Medical Association

1996 - 2000

American Medical Association

1996 - 2012

Selected Presentations & Talks

Local Presentations

2025. Systemic Therapy for Advance, Progressive Medullary Thyroid Carcinoma. Conference. Endocrine Fellows Foundation Onco-Endocrinology, Echo Program-Virtual. Houston, Texas, US.
2025. Thyroid Cancer, 2025. Conference. Comprehensive Board Review in Hematology and Medical Oncology-Virtual. Houston, Texas, US.
2024. Thyroid Cancer, 2024. Conference. Hematology and Medical Oncology Board Review-Virtual. Houston, Texas, US.
2023. An Overview of Medullary Thyroid Carcinoma and Contemporary Approaches to Care. Conference. Bayer Experiential Training Program. Houston, Texas, US.
2023. How to Ace the Interview. Invited. GME Competency Lecture Series- Virtual. Houston, Texas, US.
2023. Thyroid Cancer. Invited. A Comprehensive Board Review in Hematology and Medical Oncology. Houston, Texas, US.
2022. Thyroid Cancer. Invited. A Comprehensive Board Review in Hematology & Medical Oncology - Virtual. Virtual, TX, US.
2022. Bone Health in the Cancer Population: A Case Based Presentation. Invited. General Internal Medicine Clinical and Research Conference. Virtual, TX, US.
2020. Medullary Thyroid Carcinoma. Invited. Endocrine APP Educational Series - Virtual. Houston, TX, US.
2020. Bone Health in the Cancer Patient. Invited. Annual Multidisciplinary Cancer Cancer Conference: Bridging Oncology and Primary Care (Conference Cancelled). Houston, TX, US.
2019. Targeted Treatment Strategies for Thyroid Cancer. Invited. Cancer Network Clinical Symposium. Houston, TX, US.
2019. Calcium Disorders. Invited. Endocrine Neoplasia APP Educational Series. Houston, TX, US.
2018. An Overview of Thyroid Cancer: Epidemiology, Risk Factors, Prognosis. Invited. Thyroid Carcinoma Preceptorship. Houston, TX, US.
2018. Bone Health in the Cancer Population: A Case-Based Presentation. Invited. Division of Internal Medicine Grand Rounds. Houston, TX, US.
2018. An Overview of Thyroid Cancer: Epidemiology, Risk Factors, Prognosis. Invited. Thyroid Carcinoma Preceptorship. Houston, TX, US.
2018. Targeted Therapies for Bone Health in Cancer Patients. Invited. Investigational Cancer Therapeutics Grand Rounds. Houston, TX, US.
2017. Bone Health 101 for Cancer Survivors. Invited. 29th Annual Cancer Survivorship Conference. Houston, TX, US.
2017. Bone Health and Breast Cancer. Invited. Breast Medical Oncology Educational Meeting. Houston, TX, US.
2016. Evaluation and Management of Calcium Disorders in a Cancer Hospital. Invited. General Internal Medicine Clinical & Research Conference. Houston, TX, US.
2016. Medullary Thyroid Carcinoma: Key Information You Should Know. Invited. Medullary Thyroid Carcinoma: Academic and Clinical Learning Summit. Houston, TX, US.
2016. Medullary Thyroid Carcinoma: Systemic Therapy. Invited. Medullary Thyroid Carcinoma: Academic and Clinical Learning Summit. Houston, TX, US.
2014. Atypical Femur Fractures at UT MD Anderson Cancer Center: A Case Series. Invited. Cancer Survivorship Conference. Houston, TX, US.
2013. Hypercalcemia - Medical Evaluation. Invited. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2013. Parathyroid Carcinoma. Invited. Multidisciplinary Parathyroid Conference. Houston, TX, US.
2012. ClinicoPathologic Conference - Tracheo-Esophageal Fistulas in Cancer Patients. Invited. Division of Medicine Cancer Survivorship Grand Rounds. Houston, TX, US.
2011. Evaluating Bone Health in Cancer Survivors. Invited. Survivorship Conference for Physicians and Health Care Professionals. Houston, TX, US.
2011. New Developments in Treatment of Advanced Medullary Thyroid Carcinoma. Invited. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2011. Calcimimetic for Hyperparathyroidism - How, Why, When?. Invited. Parathyroid Multidisciplinary Conference. Houston, TX, US.
2010. MEN Clinic. Invited. ACS Site Visit. Houston, TX, US.
2010. New Targeted Therapies for Advanced Medullary Thyroid Carcinoma: The Future Looks Bright. Invited. MEN Patient Conference. Houston, TX, US.
2010. Bone Health in Cancer Patients. Invited. Bone Disease Program of Texas. Houston, Texas, US.
2010. Molecularly Targeted Therapies for Differentiated Thyroid Carcinoma - Going Beyond Radioiodine. Invited. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2009. Bone Health in Cancer Survivors. Invited. Division of Internal Medicine Survivorship Grand Rounds. Houston, TX, US.
2007. Non-islet cell tumor hypoglycemia. Invited. Department of Endocrine Neoplasia and Hormonal Disorders Recruitment Seminar. Houston, TX, US.
2006. Short-term use of teriparatide in the treatment of postoperative hypocalcemia. Invited. Department of Endocrine Neoplasia and Hormonal Disorders Research Conference. Houston, TX, US.
2006. Short-term use of teriparatide in the treatment of postoperative hypocalcemia. Invited. Department of Head and Neck Surgery Research Conference. Houston, TX, US.

Regional Presentations

2025. Medullary Thyroid Carcinoma. Invited. AACE Endocrine University- Virtual, US.
2025. Multiple Endocrine Neoplasia, Type 1: What's New in the 2025 Consensus Statement and Guidelines for Best Practice?. Invited. 2025 Annual Meeting of Michigan Association of Endocrinologists. Dearborn, Michigan, US.
2024. The Role of Imaging in the Management of Differentiated Thyroid Carcinoma. Conference. Annual Meeting of AACE. New Orleans, Louisiana, US.
2024. Session II: Differentiated Thyroid Cancer. Invited. ITOG 2024 Annual Meeting. Ponte Verde, Florida, US.
2024. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University-Virtual, US.
2023. Medullary Thyroid Carcinoma. Conference. AACE Endocrine University-Virtual, US.
2022. Updates on Medullary Thyroid Carcinoma. Invited. Annual Meeting of the Florida Endocrine Association. Key Largo, FL, US.
2021. Update on Advanced Thyroid Cancer: Targeting Treatment to Molecular Testing. Invited. New England Endocrine Alliance 13th Annual Meeting. Virtual, US.
2020. Medullary Thyroid Carcinoma. Invited. Medullary Thyroid Carcinoma. Virtual, MA, US.
2019. Differentiated Thyroid Cancer: Evolution of New Treatment Strategies. Invited. Differentiated Thyroid Cancer: Evolution of New Treatment Strategies. Philadelphia, PA, US.
2019. Cancer-Related Bone Loss and Management. Invited. Cancer-Related Bone Loss and Management. Philadelphia, PA, US.
2017. Hypoparathyroidism: A Case-Based Discussion. Invited. Hypoparathyroidism: A Case-Based Discussion. San Antonio, TX, US.
2016. Update on Multiple Endocrine Neoplasia, Type 1. Invited. Update on Multiple Endocrine Neoplasia, Type 1. Phoenix, AZ, US.
2013. Off label use of sorafenib in patients with differentiated thyroid cancer: focus on tolerability profile. Conference. Texas-American Association of Clinical Endocrinologists Annual Meeting/TESS Surgical Symposium. Austin, TX, US.
2013. Electrolyte Abnormalities. Invited. TAPA 38th Annual Spring Conference. Houston, TX, US.
2008. Clinical Challenges of Osteoporosis. Invited. NOF Regional Meeting. Houston, TX, US.

National Presentations

2025. RET Inhibitors in Medullary Thyroid Carcinoma-Podcast. OnlineOnly. Podcast-Interviewed by Desai K Medscape, US.
2025. Medullary Thyroid Carcinoma: The Spectrum of Treatments. Invited. 28th International Thyroid Cancer Survivors Conference. Houston, Tx, US.
2025. Medullary Thyroid Carcinoma: What Every Patient and Caregiver Should Know About It. Invited. 28th International Thyroid Cancer Survivors Conference. Houston, TX, US.
2025. Sequencing Systemic Therapies in Medullary Thyroid Carcinoma. Invited. 94th Annual Meeting of the American Thyroid Association. Scottsdale, Arizona, US.
2025. Targeted Therapies for Advance Thyroid Cancer. Conference. WCTC 2025. Boston, Massachusetts, US.
2025. Developing a Career in Thyroid Cancer: Insight from Endocrinologist, Oncologists, and Surgeons. Panelist. WCTC 2025. Boston, Massachusetts, US.
2025. Advances in the Treatment of Medullary Thyroid Carcinoma. Conference. SPED Puerto Rico, US.
2025. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University-Virtual, US.
2024. Medullary Thyroid Carcinoma. Conference. AACE Endocrine University, American Association of Clinical Endocrinologists. virtual, US.
2024. ATA Guidelines Update: Medullary Thyroid Cancer – Systemic Therapies. Conference. 93rd Annual Meeting of the American Thyroid Association American Thyroid Association. Chicago, IIllinois, US.
2024. Medullary Thyroid Carcinoma: What Every Patient and Caregiver Should Know About It,. Conference. 27th International Thyroid Cancer Survivors' Conference. Houston, Texas, US.
2024. Medullary Thyroid Carcinoma: The Spectrum of Treatments. Conference. 27th International Thyroid Cancer Survivors' Conference. Houston, Texas, US.
2023. Thyroid Cancer - Bedside to Bench to Bedside From a Clinician's Perspective. Invited. E. Chester Ridgway Trainee Conference. Washington DC, US.
2023. Medullary Thyroid Carcinoma. Invited. Clinical Endocrinology Update. Virtual, US.
2023. Update on Management of Medullary Thyroid Carcinoma. Invited. TIRO x MDS. Virtual, US.
2023. Webinar: Medullary Thyroid Carcinoma - Current Landscape of Systemic Therapy in Advanced MTC. Conference. Endocrine Cancers Special Interest Group. Virtual, US.
2023. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University - Virtual. Virtual, US.
2022. Clinical Management of Medullary Thyroid Carcinoma. Conference. NANETS Multidisciplinary NET Medical Symposium 2022. Washington, DC, US.
2022. Medullary Thyroid Carcinoma: What is it and what do I do now?. Conference. 24th Annual Thyroid Cancer Survivors' Conference - Virtual, US.
2022. Ask a doctor your questions about medullary thyroid cancer. Conference. 24th Annual Thyroid Cancer Survivors Conference - Virtual, US.
2022. Redifferentiation Strategy & Neoadjuvant Therapy. Conference. ENDO2022 - Annual Meeting for Endocrine Society. Atlanta, GA, US.
2022. Targeted Therapies in Advanced Thyroid Cancer (Moderator: Mimi Hu, MD). Conference. Annual Meeting of AACE. San Diego, CA, US.
2022. Thyroid Cancer Tumor Board (Moderator, Lead Presenter). Conference. Annual Meeting of AACE. San Diego, CA, US.
2022. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University - Virtual. Virtual, US.
2021. Advances in the Management of Metastatic and Aggressive Thyroid Cancer. Conference. AACE2021 Middle East Conference - Virtual. Virtual.
2021. Clinical Perspectives on Molecular Testing and Personalized Thyroid Cancer Therapy. Conference. 90th Annual Meeting of the American Thyroid Association - Virtual. Virtual, US.
2021. Resiliency and Navigating Your Career. Conference. Early Career Forum 2021 - Virtual, US.
2021. Case Presentations on Medullary Thyroid Cancer. Conference. Trainees and Career Advancement Committee - Virtual, US.
2021. RET Inhibitors in Advanced Medullary Thyroid Carcinoma. Conference. 17th International Workshop on Multiple Endocrine Neoplasia - Virtual. Virtual.
2021. Molecular Drivers of Aggressive Endocrine Neoplasms: Co-Chair. Conference. ENDO 2021 Annual Meeting - Virtual, US.
2021. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University - Virtual, US.
2020. Case-Based Perspectives on RET-Altered Solid tumors. Conference. Case-Based Perspectives on RET-Altered Solid tumors. Virtual, TX, US.
2020. Panel Discussion: Updates from the MTC & MEN2 Registry. Conference. 23rd International Thyroid Cancer Survivors' Conference - Virtual, US.
2020. Ask the Expert: AYA Thyroid Cancer. Conference. Stupid Cancer - Virtual Webinar, US.
2020. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Conference. 2020 Annual Meeting - Virtual. Chicago, IL, US.
2020. Medullary Thyroid Carcinoma: How can mutational findings influence treatment decisions?. Conference. Spring Meeting of the ATA - Virtual Meeting. New York City, NY, US.
2020. Effective Teaching Strategies. Conference. ENDO 2020. San Francisco, CA, US.
2020. Thyroid Cancer: What You Need to Know. Conference. AACE Endocrine University. Houston, TX, US.
2019. Osteoporosis: Diagnosis and Treatment. Conference. Osteoporosis: Diagnosis and Treatment. Key West, FL, US.
2019. Disorders of Calcium Metabolism. Conference. Disorders of Calcium Metabolism. Key West, FL, US.
2019. Thyroid Cancer Tumor Board. Conference. 89th Annual Meeting of American Thyroid Association. Chicago, IL, US.
2019. Redifferentiation RAI Therapy in Patients with Metastatic Papillary, Follicular and Poorly Differentiated Thyroid Cancer. Conference. 89th Annual Meeting of American Thyroid Association. Chicago, IL, US.
2019. Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma Patients Treated with Tyrosine Kinase Inhibitors Cabozantinib and Vandetanib. Conference. 89th Annual Meeting of American Thyroid Association. Chicago, IL, US.
2019. Tumor Board. Conference. E. Chester Ridgway Trainee Conference. Chicago, IL, US.
2019. Targeting Driver Mutations in the Treatment of Advanced Thyroid Cancer. Conference. 22nd International Thyroid Cancer Survivors' Conference. Denver, CO, US.
2019. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of LOXO-292 in Patients with Completely Resected, Non-Metastatic, RET-Mutant Medullary Thyroid Cancer and Rapid Calcitonin or CEA Doubling Time. Conference. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of LOXO-292 in Patients with Completely Resected, Non-Metastatic, RET-Mutant Medullary Thyroid Cancer and Rapid Calcitonin or CEA Doubling Time. New York, NY, US.
2019. Emerging Therapies in MTC: RET Inhibitor BLU-667. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Thyroid Cancer - What You Need to Know. Conference. AACE Endocrine University. Rochester, MN, US.
2018. Short-Call Oral Presentation of Clinical Activity of Selective RET Inhibitor, BLU-667, in Advanced RET-Altered Thyroid Cancers: Updated Results from the Phase I ARROW Study. Conference. 88th Annual Meeting of the American Thyroid Association. Washington, DC, US.
2018. Discovery of RET Alteration and Clinical Impacts. Conference. 88th Annual Meeting of the ATA. Washington, DC, US.
2018. Medullary Thyroid Cancer. Conference. 2018 Ridgway Trainee Conference. Washington, DC, US.
2018. Clinical activity of BLU-667, a highly potent and selective RET inhibitor in advanced, RET-altered thyroid cancer. Conference. International Thyroid Oncology Group Annual Meeting. Los Angeles, CA, US.
2018. Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors. Conference. AACR Annual Meeting. Chicago, IL, US.
2018. Thyroid Cancer - What You Need to Know. Conference. AACE Endocrine University. Rochester, MN, US.
2018. Metastatic Differentiated and Medullary Thyroid Cancer - When to Start Systemic Therapy and How to Monitor. Conference. Advances in Medical & Surgical Management of Thyroid Cancer. Phoenix, AZ, US.
2018. Radioactive Iodine Therapy Considerations. Conference. Advances in Medical & Surgical Management of Thyroid Cancer. Phoenix, AZ, US.
2017. The Utility of the Calcitonin (Ctn) to Carcinoembryogenic Antigen (CEA) Ratio in Prognostication of Medullary Thyroid Carcinoma (MTC). Conference. 3rd World Congress on Thyroid Cancer Scientific Meeting. Boston, MA, US.
2017. Osteoporosis: Diagnosis and Treatment and Clinical Cases. Conference. Osteoporosis: Diagnosis and Treatment and Clinical Cases. Hilton Head, SC, US.
2017. Disorders of Calcium Metabolism. Conference. Disorders of Calcium Metabolism. Hilton Head, SC, US.
2017. Thyroid Cancer - What You Need to Know. Conference. AACE Endocrine University. Rochester, MN, US.
2017. The Highs and Lows of Calcium and Sodium Balance in a Cancer Center. Conference. Onco-Internal Medicine Symposium. Houston, TX, US.
2017. Evaluation and Management of Medullary Thyroid Cancer Patients, Panelist. Conference. 7th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Houston, TX, US.
2017. Systemic Therapy for Medullary Thyroid Cancer. Conference. 7th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Houston, TX, US.
2017. Hypercalcemia and Parathyroid Neoplasia, Panelist. Conference. 7th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Houston, TX, US.
2017. Systemic Therapy for Advanced Thyroid Cancer - Why? What? When? How?. Conference. Advances in Medical & Surgical Management of Thyroid Cancer Meeting. Tampa, FL, US.
2017. Advanced Case Discussions, Panelist. Conference. Advances in Medical & Surgical Management of Thyroid Cancer. Tampa, FL, US.
2016. Immunotherapy-Related Destructive Thyroiditis: A Cancer Center Experience. Conference. American Thyroid Association 86th Annual Meeting. Denver, CO, US.
2016. Meet the Professor Workshop: Management of Patients with Medullary Thyroid Cancer. Conference. American Thyroid Association 86th Annual Meeting. Denver, CO, US.
2016. Osteoporosis: Diagnosis and Management. Conference. Osteoporosis: Diagnosis and Management. Cape Cod, MA, US.
2016. Disorders of Calcium Metabolism. Conference. Disorders of Calcium Metabolism. Cape Cod, MA, US.
2016. Osteoporosis: Diagnosis and Treatment. Conference. Osteoporosis: Diagnosis and Treatment. Yosemite, CA, US.
2016. Disorders of Calcium Metabolism. Conference. Disorders of Calcium Metabolism. Yosemite, CA, US.
2016. Medullary Thyroid Cancer with Bone Metastases and the Effect of Antiresorptive Agents on Skeletal Related Events: Experience at MD Anderson Cancer Center (Late Breaking Oral Presentation). Conference. Endocrine Society Annual Meeting. Boston, MA, US.
2016. Circulating Tumor Cells (CTCs) in Metastatic Papillary Thyroid Cancer: Report of a Case-Control Pilot Study (Oral Podium Presentation). Conference. Endocrine Society Annual Meeting. Boston, MA, US.
2016. Thyroid Cancer - What You Need to Know. Conference. AACE Endocrine University. Rochester, MN, US.
2016. Systemic Treatment for Differentiated and Medullary Thyroid Carcinoma - What, Why, When and How?. Conference. Advances in Medical & Surgical Management of Thyroid Cancer Meeting. Phoenix, AZ, US.
2015. Medullary Thyroid Carcinoma: Key Information You Should Know. Conference. 18th International Thyroid Cancer Survivors' Conference. St. Louis, MO, US.
2015. Medullary Thyroid Carcinoma: Questions My Patients Ask Me. Conference. 18th International Thyroid Cancer Survivors' Conference. St. Louis, MO, US.
2015. Systemic Therapy for Advanced Medullary Thyroid Carcinoma. Conference. 6th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Houston, TX, US.
2015. Evaluation and Management of Medullary Thyroid Cancer Patients, Panelist. Conference. 6th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Houston, TX, US.
2015. Hypophysitis in the age of cancer immunotherapy: experience in a large cancer center. Conference. 2015 Endocrine Society Annual Meeting. San Diego, CA, US.
2015. Salvage therapy: when a tyrosine kinase inhibitor fails in advanced medullary thyroid cancer. Conference. 2015 Endocrine Society Annual Meeting. San Diego, CA, US.
2015. Accuracy of data collected in a hereditary cancer registry, the MEN2 experience. Conference. 10th Annual Meeting. Las Vegas, NV, US.
2014. Advanced Thyroid Carcinoma and Rise of Oncologic Endocrinology. Conference. Advanced Thyroid Carcinoma and Rise of Oncologic Endocrinology. Rochester, MN, US.
2014. Patients Rely on Physicians to Inform Them about New Genetic Tests for Hereditary Cancer Syndromes. Conference. Society of Surgical Oncology Annual Meeting. Phoenix, AZ, US.
2013. Fatigue in Thyroid Cancer Patients. Conference. Fatigue in Thyroid Cancer Patients. Bethesda, MD, US.
2013. Update on Novel Therapies in Thyroid Cancer - Case Presentations. Conference. Annual Meeting of the American Thyroid Association. San Juan, PR, US.
2013. Denosumab Treatment of Persistent or Relapsed Hypercalcemia of Malignancy. Conference. Denosumab Treatment of Persistent or Relapsed Hypercalcemia of Malignancy. Baltimore, TX, US.
2013. Outcomes of Patients with Poorly Differentiated Thyroid Cancer of Follicular Origin Treated with First Line Sorafenib. Conference. Outcomes of Patients with Poorly Differentiated Thyroid Cancer of Follicular Origin Treated with First Line Sorafenib. San Juan, PR, US.
2013. Survival and Efficacy of Salvage Tyrosine Kinase Inhibitors after First Line Sorafenib Failure in Patients with Advanced Differentiated Thyroid Cancer. Conference. Survival and Efficacy of Salvage Tyrosine Kinase Inhibitors after First Line Sorafenib Failure in Patients with Advanced Differentiated Thyroid Cancer. San Juan, PR, US.
2013. Medullary Thyroid Carcinoma - Novel Chemotherapies. Conference. Medullary Thyroid Carcinoma - Novel Chemotherapies. Philadelphia, PA, US.
2013. Medullary Thyroid Carcinoma: Q&A Session. Conference. Medullary Thyroid Carcinoma: Q&A Session. Philadelphia, PA, US.
2013. Salvage therapy with tyrosine kinase inhibitors (TKIs) for differentiated thyroid carcinoma (DTC) after first line sorafenib failure. Conference. 2013 Endocrine Society Annual Meeting. San Francisco, CA, US.
2013. Oncologic Endocrinology. Conference. American Association of Clinical Endocrinologists. Phoenix, AZ, US.
2013. Evaluation of Patients with Hypercalcemia. Conference. 5th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Houston, TX, US.
2012. Medullary Thyroid Carcinoma. Conference. 15th International Survivor's Annual Conference. Chicago, IL, US.
2011. Evaluation of Patients with Hypercalcemia. Conference. 4th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2011. Hypercalcemia and Parathyroid Neoplasia Case Presentations, Panelist. Conference. 4th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2010. New Developments in Medical Management of Medullary Thyroid Carcinoma. Conference. ThyCa Annual Meeting. Dallas, TX, US.
2009. Management of Medullary Thyroid Carcinoma Case Presentations, Panelist. Conference. 3rd Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2009. Evaluation and Management of Hypercalcemia. Conference. 3rd Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2009. Bone Health in Young Women. Conference. Bone Health in Young Women. Dallas, TX, US.
2008. Medical Management of Medullary Thyroid Carcinoma. Conference. ThyCa Annual Meeting. St. Louis, MO, US.
2007. Postoperative hypoparathyroidism and the role of short-term teriparatide therapy. Conference. Advances in Mineral Metabolism/ASBMR John Haddad Young Investigators Meeting. Snowmass, CO, US.
2007. Drug Monitoring and Association of Osteonecrosis of the Jaw With Bisphosphonates. Conference. Advances in Mineral Metabolism/ASBMR John Haddad Young Investigators Meeting. Snowmass, CO, US.
2006. Short-term use of teriparatide for postoperative hypocalcemia. Conference. Endocrine Fellows Foundation - Osteoporosis Conference. Atlanta, GA, US.

International Presentations

2025. Acquired Resistance to RET- Inhibitors in Medullary Thyroid Carcinoma- Virtual. Invited. ITOG Educational Program Webinar, US.
2025. Advances in the Treatment of Medullary Thyroid Carcinoma. Conference. 17th International Thyroid Congress. Rio de Janeiro, BR.
2025. American Thyroid Association's Guidelines Update: Medullary Thyroid Cancer Systemic Therapies. Conference. 19th International World Men Workshop. Sao Paulo, BR.
2025. Severe Peripheral Vascular Disease in Patients Treated with Pralsetinib. Conference. ITOG 2025 Annual Meeting. Ann Arbor, US.
2025. Metabolic Bone Disease. Conference. Medical Education Resources. Montego Bay, JM.
2025. Endocrinology Cases: Calcium Disorders and Osteoporosis. Conference. Montego Bay, JM.
2025. Disorders of Calcium Metabolism. Conference. Medical Education Resources. Montego Bay, JM.
2025. Osteoporosis: Diagnosis and Treatment. Conference. Medical Education Resources. Montego Bay, JM.
2024. Medullary Thyroid Carcinoma: Updates on Evaluation and Management. Invited. CODHy. Shanghai, CN.
2023. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer. Conference. ESMO Congress 2023. Madrid, ES.
2023. Postoperative Management in Differentiated Thyroid Cancer. Conference. WCTC 2023. London, GB.
2023. Advanced Training in Endocrine Surgery and Thyroid Endocrine Oncology: A Session for Endocrinologists and Surgeons. Conference. WCTC 2023. London, GB.
2023. Medullary Thyroid Carcinoma Debate: Early Initiation of RET-Inhibitors. Conference. ITOG 2023 Annual Meeting. Naples, IT.
2023. Efficacy and Safety of Selective RET-Inhibitors in Hereditary MTC: A Real-World Experience. Conference. 18th International World MEN Workshop. Marseille, FR.
2023. Management of Advanced RET-Positive Medullary Thyroid Carcinoma. Conference. 18th International World MEN Workshop. Marseille, FR.
2022. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Evaluating the Relationship Between Somatic Alteration Profile and Disease Aggressiveness. Conference. 91st Annual Meeting of the American Thyroid Association. Montreal, CA.
2022. Update ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Conference. 91st Annual Meeting of the American Thyroid Association. Montreal, CA.
2022. Meet the Professor: When to Start Systemic Therapy in Advanced Thyroid Cancer. Conference. 91st Annual Meeting of the American Thyroid Association. Montreal, CA.
2022. BRAF +/- MEK Inhibitor Therapy in BRAF V600E-Mutated Differentiated Thyroid Carcinoma: Does the Presence of a TERT promoter (pTERT) Mutation Influence Therapeutic Response?. Conference. 91st Annual Meeting of the American Thyroid Association. Montreal, CA.
2021. Medullary Thyroid Cancer: New Players on the Stage, Current Challenges and Unmet Needs. Conference. 18th Annual ENETS Conference - Virtual. Virtual, DE.
2020. Results from the Registrational Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Mutation-Positive Medullary Thyroid Cancer. Conference. ESMO Congress 2020 - Virtual. Madrid, ES.
2017. Neoadjuvant vemurafenib in patients with locally advanced papillary thyroid cancer (PTC). Conference. 40th Annual Meeting of the European Thyroid Association. Belgrade, RS.
2015. Calcium Disorders. Conference. Calcium Disorders. Grand Cayman, KY.
2015. Male Hypogonadism. Conference. Male Hypogonadism. Grand Cayman, KY.
2015. Female Hyperandrogenic Disorders. Conference. Female Hyperandrogenic Disorders. Grand Cayman, KY.
2013. Management of Complications After Thyroid Surgery, Panelist. Conference. Management of Complications After Thyroid Surgery, Panelist. Toronto, CA.
2012. Vandetanib in Medullary Thyroid Cancer Study - Background. Conference. AstraZeneca Vandetanib Investigator's Meeting. Prague, CZ.
2010. Sunitinib in progressive metastatic medullary thyroid cancer. Conference. 14th International Thyroid Congress. Paris, FR.
2009. Phase I trial of combination sorafenib and tipifarnib: update on the experience in advanced differentiated thyroid cancer and medullary thyroid cancer. Conference. World Congress on Thyroid Cancer Scientific Meeting. Toronto, CA.

Formal Peers

2025. An Update on the Evaluation and Management of Medullary Thyroid Carcinoma. Houston, Texas, US.
2024. Update on Management of Advanced Medullary Thyroid Carcinoma. London, UK, GB.
2024. Update on Management of Advanced Medullary Thyroid Carcinoma. Farmington, CT, US.
2024. Advanced Thyroid Cancer: Management Beyond Surgery and RAI. Tampa, FL, US.
2024. Medullary Thyroid Carcinoma: Updates on Evaluation and Management, US.
2023. Update on the Management of Advanced Thyroid Cancer, US.
2023. Advanced Thyroid Cancer Management Beyond RAI, US.
2023. Medullary Thyroid Carcinoma: Systemic Treatments and Management. Invited. Virtual, MI, US.
2023. Advanced Thyroid Cancer: Targetable Mutations and Spectrum of Therapeutics. Invited. Virtual, RI, US.
2023. Medullary Thyroid Carcinoma: Update on Evaluation and Management. Invited. Virtual, CA, US.
2022. Update on Medullary Thyroid Carcinoma. Invited. Virtual, NJ, US.
2022. Thyroid Cancer. Invited. Houston, TX, US.
2021. Medullary Thyroid Carcinoma. Invited. Stony Brook (Virtual), NY, US.
2021. Medullary Thyroid Carcinoma. Invited. Palo Alto (Virtual), CA, US.
2020. Medullary Thyroid Carcinoma and MEN2 Syndromes. Invited, NJ, US.
2020. Overview of Driver Genes in Differentiated and Medullary Thyroid Cancer and Update on RET-Inhibitors. Invited, US.
2020. Overview of Driver Genes in Differentiated and Medullary Thyroid Cancer and Update on RET-Inhibitors. Invited. Sao Paulo, BR.
2020. Differentiated Thyroid Cancer: Overview and Spectrum of Treatments. Invited, CA, US.
2020. Advanced Thyroid Cancer: Update on Treatments Based on Driver Mutations. Invited. Phoenix, AZ, US.
2019. Medullary thyroid cancer and treatment landscape for this rare disease. Invited, US.
2019. Medullary Thyroid Cancer: Review and Update on New Therapeutic Options for Advanced Disease. Invited. Rochester, NY, US.
2019. Medullary Thyroid Carcinoma: Update on Systemic Therapies. Invited. Houston, TX, US.
2019. Cancer-Related Bone Loss and Management. Invited. Philadelphia, PA, US.
2018. Medullary Thyroid Cancer Clinic Day. Invited. Bethesda, MD, US.
2018. Medical management of medullary thyroid carcinoma. Invited. Rome, IT.
2017. Medullary Thyroid Carcinoma. Invited. East Providence, RI, US.
2017. Oncologic Endocrinology: Evolution of a Super-Specialty. Invited. Houston, TX, US.
2014. Cancer: Bad to the Bone. Invited. Nashville, TN, US.
2007. Postoperative hypoparathyroidism and the role of short-term teriparatide therapy. Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2019 - 2023
Title:	A novel natural history study of medullary thyroid carcinoma: Incorporating the patient perspective to inform advanced disease management
Funding Source:	Food and Drug Administration (FDA)
Role:	Collaborator
ID:	1R01FD006650-01

Selected Publications

Peer-Reviewed Articles

Fournier I, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head Neck 48(1):237-245, 2026. e-Pub 2025. PMID: 40891104.
Brinkman AK, Salami-Henry AY, Aaron-Brija LA, Hannah FM, Hu MI, Hwang LL, Patel RP, Rollins JL, Sherman SI, Williams JK, Kikani NJ, Weitzman SP. Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid Dysfunction. JCO Oncol Pract:OP2500440, 2025. e-Pub 2025. PMID: 41418091.
Maniakas A, Wilde DC, Fournier I, Hyde EK, Xu L, Wang JR, Gross ND, Sturgis EM, Banuchi V, Busaidy NL, Cabanillas ME, Iyer P, Dadu R, Waguespack SG, Hu MI, Gunn GB, Kwon M, Ahmed S, Williams MD, Zafereo ME. Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival. Head Neck, 2025. e-Pub 2025. PMID: 41059669.
Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, Hu MI, Ge MH, Wadsley J, Vaisman F, Kopeckova K, Krajewska J, Olvera D, Churchill C, Maeda P, Gilligan AM, Lin Y, Payakachat N, Robinson B, Hadoux J, Brose MS. Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer. Thyroid 35(10):1162-1172, 2025. e-Pub 2025. PMID: 40828665.
Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A,, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series with Operative Techniques. Head & Neck. Head & Neck, 2025. e-Pub 2025. PMID: 40747656.
Shariq, O, Waguespack, SG, Hamidi, S, Kensing, BC, Hu, MI, Skefos, CM, Perrier, ND. Approach to the Patient: Hereditary Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism 110(9):2685-2697, 2025. e-Pub 2025. PMID: 40105880.
Deschler-Baier, B, Konda, B, Massarelli, E, Hu, MI, Wirth, L, Xu, X, Wright, J, Clifton-Bligh, RJ. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 110(3):e600-e606, 2025. e-Pub 2025. PMID: 38661071.
Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
Hamidi, S, Yedururi, S, Hu, MI, Busaidy, NL, Sherman, SI, Jimenez, C, Grubbs, EG, Maniakas, A, Zafereo, M, Subbiah, V, Waguespack, SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2025. e-Pub 2024. PMID: 39630530.
Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2024. e-Pub 2024. PMID: 39662038.
Szabo Yamashita, T, Williams-Perez, S, Ehsan, S, Mulder, M, Kronenfeld, D, Huang, CY, Zhao, H, Merriman, K, Peterson, SK, Hu, MI, Zafereo, M, Sosa, JA, Grubbs, EG. The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry. Thyroid 34(9):1117-1125, 2024. e-Pub 2024. PMID: 38984944.
Hensley, SG, Hu, MI, Bassett Jr, R, Ying, AK, Zafereo, M, Perrier, ND, Busaidy, NL, Hyde, S, Grubbs, EG, Waguespack, SG. Pediatric Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism 109(9):2256-2268, 2024. e-Pub 2024. PMID: 38441533.
Sarah Hamidi, Armeen Mahvash, Hu MI. Paraneoplastic Diarrhea from Medullary Thyroid Carcinoma Resolved with Yttrium-90 Radioembolization of Liver Metastases. JCEM Case Rep 2(8):103, 2024. e-Pub 2024. PMID: 39076377.
Shirali, AS, Hu, MI, Chiang, YJ, Graham, PH, Fisher, SB, Sosa, JA, Perrier, ND, Brown, S, Holla, V, Dadu, R, Busaidy, NL, Sherman, SI, Cabanillas, ME, Waguespack, SG, Zafereo, M, Grubbs, EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients. Journal of the Endocrine Society 8(6), 2024. e-Pub 2024. PMID: 38660141.
Maniakas, A, Sullivan, A, Hu, MI, Busaidy, NL, Cabanillas, ME, Dadu, R, Waguespack, SG, Fisher, SB, Graham, PH, Gross, N, Grubbs, EG, Perrier, ND, Wang, RJ, Gunn, GB, Garden, AS, Megahed, R, Navuluri, S, Li, X, Williams, MD, Zafereo, M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head and Neck 46(2):328-335, 2024. e-Pub 2024. PMID: 38009416.
Subbiah V*, Hu MI*, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alongso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzman S, Brose MS. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid 34(1):26-40, 2024. e-Pub 2024. PMID: 38009200.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ, LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. New England Journal of Medicine 389(20):1851-1861, 2023. e-Pub 2023. PMID: 37870969.
El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 108(3):507-528, 2023. e-Pub 2023. PMID: 36545746.
Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 33(1):129-132, 2023. e-Pub 2023. PMID: 36503246.
Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer. Oral Dis 28(1):193-201, 2022. e-Pub 2022. PMID: 33274559.
Hu MI, Subbiah V, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW). Lancet Diabetes Endocrinol 9(8):491-501, 2021. e-Pub 2021. PMID: 34118198.
Shojaie D, Hoffman AS, Amaku R, Cabanillas ME, Sosa JA, Waguespack SG, Zafereo ME, Hu MI, Grubbs EE. Decision making when cancer becomes chronic. JMIR Form Res 5(7):e27484, 2021. e-Pub 2021. PMID: 34269691.
Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. J Clin Endocrinol Metab 106(8):2198-2207, 2021. e-Pub 2021. PMID: 34009369.
Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis. Endocr Relat Cancer 28(7):419-31, 2021. e-Pub 2021. PMID: 33890870.
Subbiah, V, Shen, T, Terzyan, SS, Liu, X, Hu, X, Patel, KP, Hu, MI, Cabanillas, ME, Amini, B, Meric-Bernstam, F, Vo, PT, Mooers, BH, Wu, J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Annals of Oncology 32(2):261-268, 2021. e-Pub 2021. PMID: 33161056.
Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head and Neck 43(1):E7-E12, 2021. e-Pub 2021. PMID: 33169506.
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
Dadu R, Bagheri-Yarmand R, Ringel MD, Grubbs EG, Zafereo M, Cote G, Gagel RF, Robinson BG, Shaw KR, Hu MI. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocrine-Related Cancer 27(8):T27-T39, 2020. e-Pub 2020. PMID: 32580150.
Krane, J, Cibas, ES, Endo, M, Marqusee, E, Hu, MI, Nasr, C, Waguespack, SG, Wirth, L, Kloos, RT. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases. Cancer Cytopathology 128(7):452-459, 2020. e-Pub 2020. PMID: 32543766.
Jozaghi, Y, Zafereo, M, Perrier, ND, Wang, RJ, Grubbs, EG, Gross, N, Fisher, SB, Sturgis, EM, Goepfert, RP, Lai, SY, Best, CJ, Busaidy, NL, Cabanillas, ME, Dadu, R, Gagel, RF, Habra, MA, Hu, MI, Jimenez, C, Sherman, SI, Thosani, S, Varghese, J, Waguespack, SG, Weitzman, SP, Ying, AK, Graham, PH. Endocrine Surgery in the Coronavirus Disease 2019 Pandemic: Surgical Triage Guidelines. Head and Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
Golant BT, Velez-Perez A, Krishnamurthy S, Guo M, Mousavi S, Hu MI, Varghese JM, Zafereo ME, Debnam JM. Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. J Clin Ultrasound 48(4):227-230, 2020. e-Pub 2020. PMID: 32045024.
Brown SJ, Waguespack SG, Chuang HH, Murphy WA, Hu MI. Detecting the Undetectable. Clinical Thyroidology 32(1):39-42, 2020. e-Pub 2020.
Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery 167(1):80-86, 2020. e-Pub 2020. PMID: 31648931.
Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Vandetanib photoinduced cutaneous toxicities. Cutis 103(5):E24-E29, 2019. e-Pub 2019. PMID: 31233590.
Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer 125(3):463-472, 2019. e-Pub 2019. PMID: 30383888.
Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF. Safety and efficacy of two starting doses of vandetanib in patients with progressive or symptomatic medullary thyroid cancer. Endocrine Related Cancer 26(2):241-50, 2019. e-Pub 2019. PMID: 30557850.
Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid 28(10):1243-1251, 2018. e-Pub 2018. PMID: 30132401.
Vodopivec DM, Silva AM, Garcia-Banigan C, Christakis I, Stewart A, Schwarz K, Hussey CS, Bassett R, Hu MI, Perrier ND. Gender Differences in Bone Mineral Density in Patients with Sporadic Primary Hyperparathyroidism. Endocrinology, Diabetes & Metabolism 1(4):e00037, 2018. e-Pub 2018. PMID: 30815565.
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov 8(7):836-849, 2018. e-Pub 2018. PMID: 29657135.
Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol 25(5):1395-1402, 2018. e-Pub 2018. PMID: 29427212.
Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the Lateral Neck Compartment in Patients with Sporadic Medullary Thyroid Cancer. Head Neck 40(1):79-85, 2018. e-Pub 2018. PMID: 29044788.
Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients with Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-99, 2017. e-Pub 2017. PMID: 28911154.
Long KL, Etzel C, Rich T, Hyde S, Perrier ND, Graham PH, Lee JE, Hu MI, Cote GJ, Gagel R, Grubbs EG. All in the Family? Analyzing the Impact of Family History in Addition to Genotype on Medullary Thyroid Carcinoma Aggressiveness in MEN2A Patients. Fam Cancer 16(2):283-289, 2017. e-Pub 2017. PMID: 27864651.
Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RET K666N Mutation. Thyroid 26(12):1744-1751, 2016. e-Pub 2016. PMID: 27673361.
Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):jc20162815, 2016. e-Pub 2016. PMID: 27662441.
Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):jc20162567, 2016. e-Pub 2016. PMID: 27575943.
Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res 31(8):1569-76, 2016. e-Pub 2016. PMID: 26896384.
Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. PMID: 27001565.
Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2016. PMID: 26206754.
Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the natural clay, Calcium Aluminosilicate Anti-Diarrheal (CASAD), in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: a pilot study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAF(V600E) -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. e-Pub 2015. PMID: 25353071.
Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, Armstrong PA, Liu P, Duvic M. Vitamin D Deficiency in Mycosis Fungoides and Sézary Syndrome Patients Is Similar to Other Cancer Patients. Clin Lymphoma Myeloma Leuk 14(6):518-524, 2014. e-Pub 2014. PMID: 25442486.
Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99(9):3144-52, 2014. e-Pub 2014. PMID: 24915117.
Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 24(7):1096-106, 2014. e-Pub 2014. PMID: 24617864.
Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):jc20133588, 2014. e-Pub 2014. PMID: 24628550.
Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aero-digestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24(5):918-22, 2014. e-Pub 2014. PMID: 24635127.
Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 98(11):E1813-9, 2013. e-Pub 2013. PMID: 24030942.
Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. J Natl Cancer Inst 105(18):1417-20, 2013. e-Pub 2013. PMID: 23990665.
Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 2013. e-Pub 2013. PMID: 23796991.
Rianon N, Alex G, Callender G, Jimenez C, Hu M, Grubbs E, Moreno M, Wathoo C, Petak S, Perrier N. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg 36(6):1320-6, 2012. e-Pub 2012. PMID: 22278606.
Landry CS, Grubbs EG, Hernandez M, Hu MI, Hansen MO, Lee JE, Perrier ND. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg 147(4):338-44, 2012. e-Pub 2012. PMID: 22184134.
Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center experience. Cancer 117(19):4381-9, 2011. e-Pub 2011. PMID: 21412758.
Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21(2):189-92, 2011. e-Pub 2011. PMID: 21186952.
Lin, S, Cheng, CJ, Lee, Y, Ye, X, Tsai, W, Kim, J, Pasqualini, R, Arap, W, Navone, NM, Tu, S, Hu, MI, Yu-Lee, LY, Logothetis, CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-5203, 2008. e-Pub 2008. PMID: 18490922.
Grubbs, EG, Rich, TA, Li, G, Sturgis, EM, Younes, MN, Myers, JN, Edeiken-Monroe, BS, Fornage, BD, Monroe, DP, Staerkel, GA, Williams, MD, Waguespack, SG, Hu, MI, Cote, G, Gagel, RF, Cohen, J, Weber, RS, Anaya, DA, Holsinger, F, Perrier, ND, Clayman, GL, Evans, DB. Recent Advances in Thyroid Cancer. Current problems in surgery 45(3):156-250, 2008. e-Pub 2008. PMID: 18346477.
Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 2008. e-Pub 2008. PMID: 18558816.
Yang, J, Fizazi, K, Peleg, S, Sikes, C, Raymond, AK, Jamal, N, Hu, MI, Olive, M, Martinez, LA, Wood, CG, Logothetis, CJ, Karsenty, G, Navone, NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Research 61(14):5652-5659, 2001. e-Pub 2001. PMID: 11454720.

Invited Articles

Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am 50(4):721-728, 2021. e-Pub 2021. PMID: 34774243.
Cabanillas ME, Hu MI, Dadu R, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am 29(6):1123-43, 2015. e-Pub 2015. PMID: 26568552.
Dadu, R, Hu MI, Grubbs EG, Gagel RF. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Recent Results Cancer Res(204):227-49, 2015. e-Pub 2015. PMID: 26494392.
Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol 11(21):2865-71, 2015. e-Pub 2015. PMID: 26403973.
Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endo Onc 1(2):203-16, 2014. e-Pub 2014.
Cabanillas ME, Hu MI, Jimenez C. Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat-and With Which Drug-Those Are the Questions. J Clin Endocrinol Metab 99(12):4390-6, 2014. e-Pub 2014. PMID: 25238206.
Glezerman IG, Hu MI, Jain RK. Response to the editor regarding "denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment". J Natl Cancer Inst 106(7), 2014. e-Pub 2014. PMID: 24906399.
Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am 43(2):423-42, 2014. e-Pub 2014. PMID: 24891170.
Hu MI, Gagel RF. Multiple endocrine neoplasia type 2. Translational Endocrinology & Metabolism 2(4):45-76, 2011. e-Pub 2011.
Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol 9(5):1-3, 2011. e-Pub 2011. PMID: 21685868.
Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract 17 Suppl 1:1-19, 2011. e-Pub 2011. PMID: 21134871.
Hoff AO, Toth B, Hu MI, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218(1):47-54, 2011. e-Pub 2011. PMID: 20946574.
Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780, 2011. e-Pub 2011. PMID: 22007339.
Hu MI, Lu H, Gagel RF. Cancer therapies and bone health. Curr Rheumatol Rep 12(3):177-85, 2010. e-Pub 2010. PMID: 20437119.
Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3(2):75-88, 2009. e-Pub 2009. PMID: 19412668.
Hu MI, Cote G, Gagel RF. RET gene: a therapeutic target in medullary thyroid carcinoma (within issue on "Recent advances in thyroid cancer"). Current Problems in Surgery 45(3):202-212, 2008. e-Pub 2008.
Jiménez C, Hu MI, Gagel RF. Medical management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. e-Pub 2008. PMID: 18502338.
Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep 5(4):170-8, 2007. e-Pub 2007. PMID: 18430392.

Review Articles

Salim HA, Agosto S, Al Qudah H, Learned K, Zafereo M, Wang J, Hu MI, Msherghi A, Busaidy N, Ucisik FE, Hamidi S, Eldaya RW, Li J, Cabanillas ME, Wintermark M. A Differentiated Thyroid Carcinoma-Specific Graded Prognostic Assessment for Brain Metastases Derivation(10):306. e-Pub 2025.
Hamidi S, Subbiah V, Cabanillas ME, Sherman SI, Vodopivec DM, Dadu R, Hu MI. Acquired Driver Fusions as a Mechanism of Resistance to Selective Ret-Inhibitors in Advanced Medullary Thyroid Carcinoma. e-Pub 2025.
Hamidi Sarah, Maniakas Anastasios, Akhave Neal S., Banuchi Victoria E., Busaidy Naifa L., Dadu Ramona, Ferrarotto Renata, Guise Theresa A., Hofmann Marie-Claude, Hosseini S. Mohsen, Hu MI, Iyer Priyanka C., Mansour Mena, Marczyk Vicente R., Chowdhuri Sinchita Roy-, Sherman Steven I., Sousa Luana G., Wang Jennifer R., Williams Michelle D., Zafereo Mark E., Waguespack Steven G., Cabanillas Maria E.. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. The Journal of Clinical Endocrinology & Metabolism, 2025. e-Pub 2025. PMID: 40568752.
Salim HA, Learned K, Zafereo M, Wang J, Msherghi A, Dagher S, Taslicay CA, Al Qudah H, Alizada S, Hu MI, Cabanillas M, Busaidy N, Hamidi S, Tawbi H, Eldaya R, Li J, Wintermark M. Whole Brain Radiation Therapy for Brain Metastases due to Thyroid Cancer. e-Pub 2025.
Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, Sherman SI, Hamidi S, Hosseini SM, Williams MD, Ahmed S, Routbort MJ, Luthra R, Roy-Chowdhuri S, San Lucas FA, Patel KP, Hong DS, Zafereo M, Wang JR, Maniakas A, Waguespack SG, E Cabanillas M. NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. NTRK Fusion 9(2025):12, 2025. e-Pub 2025. PMID: 39983078.
Hamidi, S, Hu, MI. RET kinase inhibitors for the treatment of RET-altered thyroid cancers. Annales d'endocrinologie 85(2):118-126, 2024. e-Pub 2024. PMID: 38342224.
Vivek Subbiah, Mohamed A Gouda, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Luz E Castellanos, Hu MI, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu. Adaptive Darwinian Off-Target Resistance Mechanisms to Selective RET Inhibition in RET Driven Cancer 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
Nardo, M, Gouda, MA, Nelson, BE, Barreto, CN, Slade, JH, Poullard, A, Zafereo, M, Hu, MI, Cabanillas, ME, Subbiah, V. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Reports Medicine 4(12), 2023. e-Pub 2023. PMID: 38118420.
Cabanillas, ME, Iyer, PC, Hu, MI. A Decade of Progress in Targeted Therapy for Advanced Thyroid Cancer. Endocrine Practice 29(3):221-227, 2023. e-Pub 2023. PMID: 35756966.
Hamidi, S, Hofmann, M, Iyer, PC, Cabanillas, ME, Hu, MI, Busaidy, NL, Dadu, R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Frontiers in Endocrinology 14, 2023. e-Pub 2023. PMID: 37435488.
Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531. Future Oncol 18(28):3143-3150, 2022. e-Pub 2022. PMID: 35969032.
Vodopivec DM, Hu MI. RET kinase inhibitors for RET-altered thyroid cancers. Ther Adv Med Oncol 14:17588359221101691, 2022. e-Pub 2022. PMID: 35756966.
Jara MA, Varghese J, Hu MI. Adverse Events Associated with Bone-Directed Therapies in Patients with Cancer. Bone 158:115901, 2022. e-Pub 2022. PMID: 33631354.
Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and Cancer: Differential Diagnosis and Treatment. CA Cancer J Clin 68(5):377-386, 2018. e-Pub 2018. PMID: 30240520.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The non-investigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2013. PMID: 23185034.

Professional Educational Materials

Tannock LR, Boelaert K, Carranza Leon BG, Clement S, Dahir KM, Donner TW, Freel M, Hu M, Irwig MS, Jonklaas J, Magill S, Reddy D, Salvatori R, Subramanian S, Vaidya A, Welt C. ESAP 2018: Endocrine Self-Assessment Program. Endocrine Society, 2018.
Tannock LR, Boelaert K, Collazo-Clavell ML, Dahir KM, Dalkin AC, Donner TW, Freel M, Green J, Hu M, Irwig MS, Jonklaas J, Magill S, Mather K, Subramanian S, Tritos NA, Welt C. ESAP 2017: Endocrine Self-Assessment Program. Endocrine Society, 2017.
Hu, Mimi. Medullary thyroid cancer. Thyroid Cancer Survivors' Association, Inc, 2014.
Hu MI. Parathyroid cancer. Phyllis Pittman Communications Ltd, 2013.
Hu MI. Bone health, 2012.

Editorials

Hu MI, Cote GJ. Medullary thyroid carcinoma: who's on first?. Thyroid 22(5):451-3, 2012. PMID: 22545752.

Abstracts

Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Sherman EJ, Tahara M, Hu MI, Lin Y, Maeda P, Wirth LJ, Capdevila J. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer. Annals of Oncology 34(S2):S187-S1060, 2023. e-Pub 2023.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Sherman EJ, Tahara M, Hu MI, Lin Y, Maeda P, Wirth LJ, Capdevila J. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer. ESMO Congress 2023 34(S2):S187-S1060, 2023. e-Pub 2023.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Sherman EJ, Tahara M, Hu MI, Lin Y, Maeda P, Wirth LJ, Capdevila J. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer (Late Breaking Abstract 3 - Presidental Symposium. Annals of Oncology 34(S2), 2023. e-Pub 2023.
Yamashita TS, Mulder M, Williams-Perez S, Cortell A, Huang CY, Zhao H, Peterson SK, Hu MI, Zafereo M, Gosness J, Sosa JA, Grubbs EG. The Multi-institutional Medullary Thyroid Cancer Collaborative Registry (MTCCoRe): Can a rare tumor registry accurately represent all affected patients?. Thyroid 33(S1):Poster 447, 2023. e-Pub 2023.
Ning M, Dudzinski SO, Busaidy NL, Dadu R, Welsh J, Hu MI, Gunn B, Wang C, Waguespack SG, Phan J, Beckham TH, Chang JY, Sherman SI, Reddy JP, Ying AK, Oreilly M, Chen A, Lee A, Gandhi SN, Liao Z, Ludmir EB, Nguyen Q, Tang C, Lin SH, Zafereo MA, Cabanillas ME. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Feasible Strategy to Defer Escalation of Systemic Therapy. Thyroid 33(S1):Late Breaking Poster 543, 2023. e-Pub 2023.
Ning M, Dudzinski SO, Busaidy NL, Dadu R, Welsh J, Hu MI, Gunn B, Wang C, Waguespack SG, Phan J, Beckham TH, Chang JY, Sherman SI, Reddy JP, Ying AK, Oreilly M, Chen A, Lee A, Gandhi SN, Liao Z, Ludmir EB, Nguyen Q, Tang C, Lin SH, Zafereo MA, Cabanillas ME. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Feasible Strategy to Defer Escalation of Systemic Therapy (Late Breaking Poster 543). Thyroid 33(S1), 2023. e-Pub 2023.
Yamashita TS, Mulder M, Williams-Perez S, Cortell A, Huang CY, Zhao H, Peterson SK, Hu MI, Zafereo M, Gosness J, Sosa JA, Grubbs EG. The Multi-institutional Medullary Thyroid Cancer Collaborative Registry (MTCCoRe): Can a rare tumor registry accurately (Poster 447. Thyroid 33(S1), 2023. e-Pub 2023.
Hadoux J, Hu MI, Brose MS, Garralda E, Spitzweg C, Reguart N, Cao CD, Forster MD, Gordoa TA, Barata T, Scalori A, Zalutskaya A, Trask P, Subbiah V. Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive TC treated with pralsetinib in the ARROW trial. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
Fazeli S, McBeath E, Gule-Monroe M, Cabanillas ME, Busaidy N, Waguespack SG, Hu MI, Jimenez C, Sherman SI, Habra MA, Cote GJ, Bassett R, Williams MD, Hofmann MC, Dadu R. BRAF +/- MEK Inhibitor Therapy in BRAF V600E-Mutated Differentiated Thyroid Carcinoma: Does the Presence of a TERT Promoter Mutation Influence Therapeutic Response?. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier ND, Brown S, Subbiah V, Holla VR, Dadu R, Busaidy NL, Sherman SI, Cabanillas ME, Waguespack SG, Zafereo M, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Evaluating the Relationship Between Somatic Alteration Profile and Disease Aggressiveness. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
Hu MI, Subbiah V, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth LJ, Garralda E, Adkins D, Godbert Y, Ahn MJ, Cassier P, Cho BC, Lin CC, Barata T, Zalutskaya A, Scalori A, Brose MS. Updated ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
Hadoux J, Hu MI, Brose MS, Garralda E, Spitzweg C, Reguart N, Cao CD, Forster MD, Gordoa TA, Barata T, Scalori A, Zalutskaya A, Trask P, Subbiah V. Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive TC treated with pralsetinib in the ARROW trial. Endocrine Abstracts 84:PS3-15-134, 2022. e-Pub 2022.
Hu MI, Subbiah V, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth LJ, Garralda E, Adkins D, Godbert Y, Ahn MJ, Cassier P, Cho BC, Lin CC, Barata T, Zalutskaya A, Scalori A, Brose MS. Updated ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Ann Oncol 33(suppl 7):S750-Ss757, 2022. e-Pub 2022.
Vodopivec DM, Chen YH, Cabanillas ME, Hu MI, Busaidy NL, Dadu R, Budde G, Malhotra M, Diersing J, Zafereo ME. A Proof-of-Concept Study for Detecting Circulating Tumor DNA in Rare Thyroid Cancers. Ann Oncol 33(suppl 7):S750-Ss757, 2022. e-Pub 2022.
Maniakas A, Sullivan A, Busaidy N, Cabanillas M, Dadu R, Risher S, Graham P, Gross N, Grubbs E, Gunn GB, Hu M, Li X, Perrier N, Waguespack S, Wang J, Williams M, Zafereo M. Decreasing Indications for Postoperative Adjuvant Radiation Therapy in Locoregionally-Advanced Medullary Thyroid Cancer. Thyroid 31(S1), 2021. e-Pub 2021.
Gordon M, Roszik J, Cabanillas ME, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Elamin YY, Cascone T, Byers LA, Blumenschein GR, Fossella FV, Naing A, Hong DS, Heymach J, Meric-Bernstram F, Subbiah V. Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials. J Clin Oncol 39(suppl 15; abstr 3117), 2021. e-Pub 2021.
Wirth LJ, Hu MI, Waguespack SG, Dosiou C, Ladenson P, Livhits MJ, Sadow PM, Krane J, Stack BC, Zafereo M, Ali SZ, Weitzman SP, Hao Y, Barbiarz J, Kennedy G, Kloos R. NTRK, RET, BRAF, and ALK fusions in thyroid fine-needle aspirates (FNAs). J Clin Oncol 39(suppl 15; abstr 6083), 2021. e-Pub 2021.
Jara M, Casteel KN, Afshar-Kharghan V, Subbiah V, Wing S, Hu MI. Paraneoplastic Eosinophilia: A Rare Finding in a Patient with Medullary Thyroid Carcinoma. J Endocrine Society 5(supplement 1):A896, 2021. e-Pub 2021.
Subbiah V, Hu MI, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Lopez PG, Amatu A, Doebele RC, Cassier PA, Keam B, Schuler MH, Zhang H, Clifford C, Palmer M, Green J, Turner CD, Curigliano G. Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET Fusion-Positive Solid Tumors. J Clin Oncol 39(suppl 3; abstr 1), 2021. e-Pub 2021.
Keam B, Hu MI, Subbiah V, Wirth L, Schuler M, Mansfield AS, Brose MS, Curigliano G, Leboulleux S, Zhu VW, Matos I, Adkins D, Baik, CS, Lopes G, Godbert Y, Sarker D, Zhang H, Turner CD, Taylor MH, Lin C. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer. Ann Onc 31(suppl_6):S1407-S1415, 2020. e-Pub 2020.
Hu MI, Subbiah V, Wirth L, Schuler M, Mansfield AS, Brose MS, Curigliano G, Leboulleux S, Zhu VW, Keam B, Matos I, Lin CC, Adkins D, Baik CS, Lopes G, Godbert Y, Sarker D, Zhang H, Turner CD, Taylor MH. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer. Ann Onc 31(suppl_4):S1026-S1033, 2020. e-Pub 2020.
Subbiah V, Hu MI, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Lopez PG, Amatu A, Loebele RC, Cassier PA, Keam B, Schuler MH, Zhang H, Clifford C, Palmer M, Green J, Turner CJ. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol 38(suppl; abstr 109), 2020. e-Pub 2020.
Brown SJ, Gruschjus SK, Waguespack SG, Dadu R, Zafereo M, Cabanillas ME, Grubbs EG, Sherman SI, Hu MI. RAS-mutated sporadic medullary thyroid cancer: A single-center experience. J Clin Oncol 38(suppl; abstr 6584), 2020. e-Pub 2020.
Gammons S, Hu MI, Zafereo ME, Busaidy NL, Perrier ND, Bassett RL, Hyde SM, Grubbs EG, Waguespack SG. Sporadic MTC in Children: Characterization of a Rare Disease. J Endocrine Society 4(Supplement_1):MON-LB015, 2020. e-Pub 2020.
Fazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy NL, Hu MI, Jimenez C, Habra MA, William M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center. J Endocrine Society 4(Supplement_1):MON-491, 2020. e-Pub 2020.
Livhits MJ, Hu MI, Waguespack SG, Wirth LJ, Ladenson PW, Stack BC, Hao Y, Babiarz JE, Kennedy GC, Kloos RT. Positive Predictive Value of TP53 Variants in Bethesda III/IV Thyroid Fine-Needle Aspirates. J Endocrine Society 4(Supplement_1):MON-LB88, 2020. e-Pub 2020.
Hu MI, Livhits MJ, Stack BC, Sherman SI, Sadow P, Ali S, Krane JF, Evans DB, Hao Y, Babiarz JE, Kennedy GC, Kloos RT. NTRK, RET, BRAF, and ALK Fusions in Thyroid Fine-Needle Aspirates (FNAs). Thyroid 29(S1), 2019. e-Pub 2019.
Brown S, Waguespack S, Chuang H, Murphy W, Hu MI. Radiologic Response by 68Gallium DOTATATE PET/CT in Patients with Medullary Thyroid Carcinoma on Systemic Therapy. Thyroid 29(S1), 2019. e-Pub 2019.
Graham PH, Habra MA, Jimenez C, Ying AK, Busaidy NL, Cabanillas ME, Zafereo M, Perrier N, Grubbs EG, Gagel RF, Sherman SI, Hu MI. Ectopic ACTH Secretion in Medullary Thyroid Cancer: A Case Series at a Cancer Center. Thyroid 29(S1), 2019. e-Pub 2019.
Hu MI, Cote GJ, Hai T, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Grubbs EG, Habra M, Jimenez J, Subbiah V, Waguespack SG, Williams MD, Zafereo M, Sherman SI. Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and Vandetanib. Thyroid 29(S1), 2019. e-Pub 2019.
Hegde A, Huang L, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Cote G, Simon G, Blumenschien G, Vassiliki A, Papadimitrakopoulou VA, Hong DS, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors in RET dependent cancers. Cancer Research 79(13 Suppl), 2019. e-Pub 2019. PMID: 33097651.
Taylor MH, Gainor JF, Hu MI, Zhu V, Lopes G, Leboulleux S, Brose MS, Schuler M, Bowles DW, Kim DW, Baik C, Garralda E, Lin CC, Adkins D, Sarker D, Curigliano G, Zhang H, Clifford C, Turner CD, Subbiah V. Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. J Clin Oncol 37(suppl):abstr 6018, 2019. e-Pub 2019.
Wirth LJ, Waguespack SG, Busaidy NL, Hu MI, Grubbs EG, Weitzman SP, Zafereo ME, Babiarz J, Hao Y, Huang J, Kennedy GC, Walsh PS, Kloos RT. Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and the potential impact on systemic therapy. J Clin Oncol 37(suppl):abstr 6087, 2019. e-Pub 2019.
Maxwell J, Busaidy N, Hu M, Perrier N, Lee J, Graham P, Cote G, Grubbs E. Novel use of a CLIA-certified CDKN2C loss assay in sporadic medullary thyroid carcinoma. AAES Proceedings, 2019. e-Pub 2019.
Agosto S, Waguespack S, Cote G, Hess K, Habra M, Jimenez C, Hu M, Sherman SI, Busaidy N, Dadu R, Tatsui C, McCutcheon I, Grubbs E, Williams M, Shah K, Cabanillas M. Brain metastases in thyroid cancer: molecular profile and institutional experience of a single tertiary referral center in the era of kinase inhibitor therapy (Presidental Abstract Award Competition). Journal of the Endocrine Society 3(S1), 2019. e-Pub 2019.
Waguespack SG, Busaidy NL, Hu MI, Grubbs EG, Weitzman SP, Wirth LJ, Zafereo ME, Babiarz JE, Hao Y, Huang J, Kennedy GC, Walse PS, Kloos RT. The genomic landscape of preoperative FNAs positive for the Afirma GSC medullary thyroid cancer classifier. Journal of the Endocrine Society 3(S1), 2019. e-Pub 2019.
Agosto S, Hu M, Thosani S, Ying A, Gagel RF, Zafereo M, Perrier N, Graham P, Williams JK, Crowder VM, Varghese J. Post-thyroidectomy hypoparathyroidism management: a prospective quality improvement initiative at a single tertiary center. Endocrine Practice 25(S1), 2019. e-Pub 2019.
Kiernan CM, Graham P, Lee JE, Perrier N, Cote G, Hu M, Grubbs E. Staging of Medullary Thyroid Carcinoma: What About MX Disease?. Thyroid 28(Suppl 1):A-140, 2018. e-Pub 2018.
Pei D, Kanji A, Williams M, Zhou J, Serpas V, Abudayyeh A, Cabanillas ME, Hu MI. Rare Presentation of Anaplastic Thyroid Carcinoma with Bilateral, Infiltrative Renal Metastases Responsive to Targeted Therapy. Thyroid 28(Suppl 1):A-140, 2018. e-Pub 2018.
Dadu R, Cabanillas ME, de Groot P, Chang JY, Tang C, Sherman SI, Busaidy NL, Waguespack SG, Hu MI, Ying A, Habra M, Menon H, Welsh J. Ipilimumab with stereotactic ablative radiation therapy (SABR): results of a thyroid cancer expansion cohort. Thyroid 28(Suppl 1):A-193, 2018. e-Pub 2018.
Hu MI, Taylor M, Wirth L, Zhu V, Doebele R, Lee DH, Matos I, Baik C, Brose M, Curigliano G, Lopes G, Kim DW, Tan D, Lin CC, Palmer M, Tugnait, M, Zhang H, Mar B, Clifford C, Wolf B, Garralda E, Ou SI, Subbiah V, Gainor J. Clinical Activity of Selective RET-Inhibitor, BLU-667, in Advanced RET-Altered Thyroid Cancers: Updated Results from the Phase I ARROW Study. Thyroid 28(Suppl 1):A-2, 2018. e-Pub 2018.
Nguyen H, Shah K, Waguespack S, Habra M, Cabanillas M, Hu M, Iyer P, Kaya D, Pitteloud M, Subudhi S, Diab A, Dadu R. Immune-Related Hypophysitis (irH) Associated with Checkpoint Inhibitor Therapy: Diagnosis, Characteristics and Long Term Follow Up. Endocrine Reviews 39(2 Suppl), 2018. e-Pub 2018.
Busaidy NL, Cabanillas ME, Sherman SI, Habra M, Dadu R, Hu MI, Jimenez C, Waguespack SE, Subbiah V, Ying A, Gagel R, Cote GJ. Emergence of V804M resistance gatekeeper mutation in sporadic medullary thyroid carcinoma patients treated with TKI tyrosine kinase inhibitors. Thyroid 27(S1):P-11, 2017. e-Pub 2017.
Jaber T, Pandit K, Williams MD, Bodurka D, Hu MI. Metastasis to the thyroid gland from cancer of the cervix: experience of a comprehensive cancer center and review of the literature. Thyroid 27(S1):A-32, 2017. e-Pub 2017.
Cabanillas ME, Busaidy NL, Zafereo M, Waguespack SG, Hu MI, Hofmann MC, Sturgis E, Sherman SI. Neoadjuvant vemurafenib in patients with locally advanced papillary thyroid cancer (PTC). European Thyroid Journal 6(suppl 1):23-118, 2017. e-Pub 2017.
Kutahyalioglu M, Ibrahim EY, Williams M, Dadu R, Habra MA, Hu M, Jimenez C, Waguespack S, Ying AK, Graham P, Busaidy N. Malignant Struma Ovarii: A Case Series. Endocrine Practice 23(Suppl 3), 2017. e-Pub 2017.
Pena I, Grubbs EG, Kanthasamy KA, Lee JE, Hu MI, Cote GJ, Fellman BM, Li Y, Clayman GK, Sturgis EM, Zafereo ME. Prognostic Factors in Surgical Patients with Sporadic Medullary Thyroid Cancer. Thyroid 26(S1):#212, 2016. e-Pub 2016.
Cote GJ, Evers C, Hu MI, Grubbs EG, Hai T, Houston, MR, Williams M, Duose DY, Mehrotra M, Busaidy N, Waguespack S, Luthra R, Sherman SI. Liquid Biopsy of CFDNA as a Predictor of Survival in Medullary Thyroid Carcinoma Patients with Somatic RET M918T Mutations. Thyroid 26(S1):#74, 2016. e-Pub 2016.
Iyer P, Cabanillas M, Waguespack S, Busaidy N, Hu M, Dadu R. Immunotherapy-related Destructive Thyroiditis: A Cancer Center Experience. Thyroid 26(S1):Oral #32, 2016. e-Pub 2016.
Xu JY, Handy BC, Waguespack SG, Hu MI, Busaidy NL, Jimenez C, Cabanillas ME, Cote GJ, Sherman SI. Effect of circulating tumor cells (CTCs) on overall survival in metastatic medullary thyroid cancer (metMTC). J Clin Oncol 34(suppl; abstr e17547), 2016. e-Pub 2016.
Xu JY, Zaidi TM, Cote GJ, Hu MI, Waguespack SG, Cabanillas ME, Ying AK, Busaidy NL, Habra MA, Shanbhag N, Truong D, Yu RK, Shete S, Katz RL, Sherman SI. Accurate detection of circulating tumor cells (CTCs) in patients with metastatic papillary thyroid cancer (MPTC) via an interphase fluorescence in situ hybridization (IFISH) assay. J Clin Oncol 34(suppl; abstr e17550), 2016. e-Pub 2016.
Kwatampora L, Hamidi V, Lewis C, Williams J, Williams MD, Hu M, Murphy W, Perrier ND, Jimenez C, Busaidy N. Parathyroid carcinoma associated with multiple brown tumors mimicking fibrous histiocytoma-a unique case of two rare conditions. Endocrine Practice 22(Suppl 2), 2016. e-Pub 2016.
Xu JY, Milton D, Rao S, Jimenez C, Habra M, Waguespack S, Ying A, Cabanillas M, Cote G, Dadu R, Grubbs E, Weitzman S, Busaidy N, Gagel R, Sellin R, Sherman SI, Hu MI. Medullary Thyroid Cancer with Bone Metastases and the Effect of Antiresorptive Agents on Skeletal Related Events: Experience at MD Anderson Cancer Center. Endocrine Reviews 37(2), 2016. e-Pub 2016.
Xu JY, Zidi T, Cote GJ, Hu MI, Waguespack SG, Cabanillas ME, Ying AK, Busaidy NL, Habra MA, Shanbhad N, Truong D, Yu RK, Shete S, Katz RL, Sherman SI. Circulating Tumor Cells (CTCs) in Metastatic Papillary Thyroid Cancer: Report of a Case-Control Pilot Study. Endocrine Reviews 37(2), 2016. e-Pub 2016.
Vodopivec DM, Silva AM, Schwarz K, Christakis I, Stewart A, Perrier ND, Hu MI. Bone Mineral Density Screening Importance in Men with Sporadic Primary Hyperparathyroidism. Endocrine Reviews 37(2), 2016. e-Pub 2016.
Weitzman SP, Waguespack SG, Ying AK, Hu MI, Cabanillas ME. Pain may represent treatment response to targeted therapy in patients with thyroid cancer. Thyroid 25(suppl 1), 2015. e-Pub 2015.
Velasco G, Hu MI, Jimenez C, Eapen G, Mulanovich VE, Cabanillas ME. Fungal infections mimicking metastatic differentiated thyroid cancer. Endocrine Practice, 2015. e-Pub 2015.
Stewart A, Williams M, Hu MI, Feng L, Lee J, Perrier N, Cabanillas M, Cote G, Grubbs EG. The role of somatic RET and RAS mutation in predicting outcome in sporadic medullary thyroid carcinoma. Proceedings for 36th Annual Meeting for the American Association of Endocrine Surgeons, 2015. e-Pub 2015.
Pitteloud MJ, Dadu R, Cabanillas ME, Shah K, Hu MI, Habra MA, Waguespack SG. Hypophysitis in the age of cancer immunotherapy: experience in a large cancer center. Endocrine Reviews, 2015. e-Pub 2015.
Patham B, Miller E, Murphy WA, Hu MI. Tenofovir-related hypophosphatemic osteomalacia and multiple fractures mimicking metastatic bone disease in a patient with hepatocellular carcinoma. Endocrine Reviews, 2015. e-Pub 2015.
Weitzman SP, Reicher KT, Dadu R, Hu MI, Jimenez C, Gardner C, Qayyum A, Hernandez M, Cabanillas ME. Salvage therapy: when a tyrosine kinase inhibitor fails in advanced medullary thyroid cancer. Endocrine Reviews, 2015. e-Pub 2015.
Trotter C, Farhood Z, Hu MI, Cabanillas M, Jackson M, Rich T, Graham P, Lee J, Perrier N, Grubbs EG. Accuracy of data collected in a hereditary cancer registry, the MEN2 experience. 10th Annual Academic Surgical Congress, 2015. e-Pub 2015.
Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, Hu MI, Jimenez C, Kopetz S, Lee JE, Sherman SI, Sellin RV, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma—a need for molecular profiling to aid in prognostication and therapeutics. J Clin Oncol 33(suppl; abstr e17012), 2015. e-Pub 2015.
Sudhakar SM, Hu MI, Kontoyiannis D, Williams MD, Ying AK, Habra MA. Mucormycosis thyroiditis - a rare cause of thyroiditis and hyperthyroidism in patients with hematological malignancies. Thyroid 24(S1):P137, 2014. e-Pub 2014.
Dadu R, Hu MI, Cleeland CS, Busaidy NL, Habra MA, Waguespack SG, Sherman SI, Ying AK, Fox P, Cabanillas M. The efficacy of the natural clay, CASAD, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: A pilot study. Thyroid 24(S1):P166, 2014. e-Pub 2014.
Dadu R, Shah K, Bassett RL, Busaidy NL, Waguespack SG, Sherman SI, Habra MA, Jimenez C, Hu MI, Ying AK, Cabanillas ME. Is there an alternative treatment option for patients with advanced papillary thyroid cancer harboring the BRAFV600E mutation. Endocrine Reviews 35(3 Suppl):OR52-4, 2014. e-Pub 2014.
Edwards BJ, Lu H, Hu MI, Saraykar S, Bunta A, West DP, Barcenas CH, Gagel RF, Hortobagyi GN, Murphy WA. Risk factors for atypical femur fractures in cancer patients. J Clin Oncol 32(Suppl; abstr e12533), 2014. e-Pub 2014.
Xu J, Gagel RF, Hu MI. Denosumab-induced refractory hypocalcemia in a patient with breast cancer and diffuse osteoblastic bone metastases and surgical hypoparathyroidism. Division of Internal Medicine 2014 Retreat, 2014. e-Pub 2014.
Misiorowski W, Hu M, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain R. Denosumab therapy for the treatment of persistent or relapsed hypercalcemia of malignancy. Osteoporosis International 25(Suppl 2):P278, 2014. e-Pub 2014.
Xu J, Gagel RF, Hu MI. Denosumab-induced refractory hypocalcemia in a patient with breast cancer and diffuse osteoblastic bone metastases and surgical hypoparathyroidism. AACE Annual Meeting:Abstract 620, 2014. e-Pub 2014.
Gucalp R, Insogna K, Hu MI, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for the treatment of hypercalcemia of malignancy refractory to IV bisphosphonates in patients with hematologic malignancies. Blood, 2013. e-Pub 2013.
Glezerman I, Insogna K, Hu MI, Chougnet CN, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain R. Denosumab for hypercalcemia of malignancy (HCM) in renally impaired patients [PO762]. J Am Soc Nephrol 24(Abstract), 2013. e-Pub 2013.
Gucalp R, Insogna K, Hu MI, Glezerman IG, Leboulleux S, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for the treatment of persistent or relapsed hypercalcemia of malignancy. 13th International Conference on Cancer-Induced Bone Disease, Miami, FL 11/2013, 2013. e-Pub 2013.
Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack SG, Hu MI, Ying A, Habra MA, Jimenez C, Sellin RV, Cote G, Sherman SI, Cabanillas ME. Survival and efficacy of salvage tyrosine kinase inhibitors after first line sorafenib failure in patients with advanced differentiated thyroid cancer. Thyroid 23(Suppl 1), 2013. e-Pub 2013.
Dadu R, Shah K, Waguespack SG, Sherman SI, Habra M, Busaidy N, Jimenez C, Ying A, Hu MI, Cabanillas ME. Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer. Thyroid 23(Suppl 1), 2013. e-Pub 2013.
Sherman SI, Michaelis C, Gornet T, Handy B, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Cote G. Overall survival is reduced in patients with detectable circulating tumor cells from metastatic medullary thyroid cancer. Thyroid 23(Suppl 1), 2013. e-Pub 2013.
Insogna K, Hu MI, Glezerman I, Leboulleux S, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain R. Denosumab treatment of persistent or relapsed hypercalcemia of malignancy (HCM). J Bone Miner Res 28(Suppl 1), 2013. e-Pub 2013.
Adili A, Chasen B, Dadu R, Williams M, Ali SK, Waguespack SG, Habra MA, Cote G, Busaidy N, Jimenez C, Hu MI, Sellin RV, Sherman SI, Cabanillas ME. Outcomes of patients with poorly differentiated thyroid cancer of follicular origin treated with first line sorafenib. Thyroid 23(Suppl 1), 2013. e-Pub 2013.
Leboulleux S, Hu MI, Glezerman I, Gucalp R, Misiorowski W, Jaccard A, Tonini G, Ying W, Braun A, Jain R. Denosumab treatment of hypercalcemia of malignancy (HCM) in patients not responding to bisphosphonate therapy. European Cancer Congress (ECCO), 2013. e-Pub 2013.
Dadu R, Busaidy N, Habra M, Hu MI, Jimenez C, Ying A, Waguespack S, Cabanillas M. Off-label use of sorafenib in patients with differentiated thyroid cancer: focus on tolerability profile. Texas-AACE Annual Meeting/TESS Surgical Symposium, Austin, TX, 08/2013, 2013. e-Pub 2013.
Cabanillas ME, Holsinger FC, Sturgis E, Habra M, Davies MA, Munsell M, Busaidy N, Hu M, Sherman SI. Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC). J Clin Oncology 31(suppl; abstr TPS6100), 2013. e-Pub 2013.
Hu MI, Glezerman I, Leboulleux X, Insogna KL, Gucalp RA, Misiorowski W, Yu BW, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Wang H, Braun A, Jain RK. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM). J Clin Oncology 31(suppl; abstr e20512), 2013. e-Pub 2013.
Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack S, Ying A, Habra M, Thosani S, Hu M, Cabanillas M. Is second-line targeted therapy beneficial in patients (pts) with differentiated thyroid cancer (DTC) after first-line sorafenib (SOR) failure?. J Clin Oncology 31(suppl; abstr e17016), 2013. e-Pub 2013.
Dadu R, Habra M, Williams MD, Hu MI. Metastatic papillary thyroid carcinoma to the kidney-30 years after initial diagnosis. Endocrine Society Annual Meeting, Houston, TX, 06/2012, 2012. e-Pub 2012.
Hu MI, Gucalp R, Insogna K, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Ying W, Yeh H. Denosumab for treatment of hypercalcemia of malignancy in patients with solid tumors or hematological malignancies refractory to IV bisphosphonates: a single-arm multicenter study. Blood(Abstracts):2483, 2011. e-Pub 2011.
Hu MI, Gucalp R, Insogna KL, Glezerman I, Bone HG, Jaccard A, Misiorowski W, Yu BW, Ying W, Yeh H. A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. J Clin Oncology 29(suppl):abstr TPS245, 2011. e-Pub 2011.
Alex G, Rianon N, Callender G, Moreno M, Jimenez C, Hu M, Grubbs E, Lee J, Perrier N. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. International Association of Endocrine Surgeons, 09/2011, 2011. e-Pub 2011. PMID: 22278606.
Alford E, Murphy WA, Shah J, Jimenez C, Lee B, Hu MI. An unusual case of acquired and rapid osteosclerosis. Endocrine Reviews 32(3):P2-151, 2011. e-Pub 2011.
Alford EM, Hu MI. Thyroxine autoantibody in a patient with Hashimoto thyroiditis and cryoglobulinemia (Presidential Poster Competition). Endocrine Reviews 32(3):P1-669, 2011. e-Pub 2011.
Cash K, Gagel R, Palmer JL, Thomas DA, Mattiuzzi G, Kantarjian HM, OBrien S, Hu M, Jimenez C, Cabanillas ME. A randomized, double blinded study of risedronate versus placebo for the prevention of bone loss in patients receiving high dose corticosteroids for the treatment of acute lymphocytic leukemia and lymphoblastic lymphoma. Blood(Abstracts):1486, 2011. e-Pub 2011.
Rich TA, Waguespack SG, Gagel R, Cote G, Ying A, Hu M, Perrier ND, Lee JE, Grubbs EG. Age-specific identification of medullary thyroid cancer (MTC) in presymptomatically screened American Thyroid Association (ATA) levels A and B RET mutation carriers. MEN Meeting, Gubbio, Italy, 9/2010, 2010. e-Pub 2010.
Williams MD, Hu MI, Clayman GL. Methylation of PEBP1, a metastasis suppressor gene in thyroid carcinoma. 14th International Thyroid Congress, Paris, France, 9/2010, 2010. e-Pub 2010.
Michaelis CL, Cote GJ, Santarpia L, Klein MJ, Gornet T, Fritsche H, Hu MI, Sherman SI. Detection of circulating tumor cells in patients with thyroid cancer. Endocrine Reviews 31(3, suppl 1):P1-540, 2010. e-Pub 2010.
Busaidy NL, DeSouza JA, Zimrin A, Swiwert TY, Villaflor VM, Poluru K, Nam J, Hu M, Waguespack SG, Vokes EE, Cohen EE. Sunitinib in progressive metastatic medullary thyroid cancer. 14th International Thyroid Congress, Paris, France, 9/2010, 2010. e-Pub 2010.
Busaidy NL, Vu T, Grubbs E, Urbauer D, Kim E, Landry C, Jimenez C, Hu MI, Waguespack SG, Gomez H, Perrier ND. 4D neck CT versus SPECT/CT using Tc99m sestamibi in the localization of parathyroid adenomas: which study and when?. Endocrine Reviews 31(3, suppl 1):P2-246, 2010. e-Pub 2010.
Ejaz S, Waguespack SG, Sellin RV, Busaidy NL, Jimenez C, Ying AK, Hu MI, Cabanillas ME, Gagel RF, Habra MA. ACTH-dependent ectopic cushing's syndrome: The University of Texas MD Anderson Cancer experience. Endocrine Reviews 31(3, suppl 1):P3-632, 2010. e-Pub 2010.
Alford EM, Cote G, Rich T, Grubbs E, Williams MD, Hu MI. RET codon Y791F mutation - not as low risk as we thought. 14th International Thyroid Congress, Paris, France, 9/2010, 2010. e-Pub 2010.
Khan MI, Murphy WA, Gagel RF, Hu MI. Long-term bisphosphonate use and risk of subtrochanteric insufficiency fractures: case review. Journal of Bone and Mineral Research 24 (Suppl 1), 2009. e-Pub 2009.
Callender GG, Moreno M, Jimenez C, Hu MI, Grubbs EG, Evans DB, Lee JE, Perrier ND. Osteocaicin: preoperative predictor of bone hunger after parathyroidectomy. American Association of Clinical Endocrinologists 18th Annual Meeting, Houston, TX, 5/2009, 2009. e-Pub 2009.
Cabanillas ME, Kurzrock R, Bidyasar S, Wheler J, Fu S, Naing A, Sherman SI, Gagel R, Waguespack S, Busaidy N, Sellin R, Hu MI, Kies M, Hong DS. Phase I trial of combination sorafenib and tipifarnib: update on the experience in advanced differentiated thyroid cancer and medullary thyroid cancer. World Congress on Thyroid Cancer Scientific Meeting, Toronto, Canada, 8/6/2009, 2009. e-Pub 2009.
Cabanillas, ME, Hong D, Waguespack S, Sherman S, Hernandez M, Hu M, Habra M, Busaidy N. Stable disease is an important endpoint in patients with progressive, differentiated thyroid cancer treated with sorafenib (#152). Thyroid 19(s1):76-77, 2009. e-Pub 2009.
Shah BA, Cote G, Evans D, Waguespack S, Hoff A, Hu, MI. Sudden death in a family with multiple endocrine neoplasia type 1 (MEN1): an association of hypercalcemia with Brugada syndrome. The Endocrine Society's 90th Annual Meeting, San Francisco, CA, June 15 -18, 2008, 2008. e-Pub 2008.
Hu MI, Busaidy NL, Sellin RV, Waguespack SG. Non-islet cell tumor hypoglycemia and inappropriate cortisol response. The Endocrine Society 89th Annual Meeting, Toronto, Canada, 6/2007, 2007. e-Pub 2007.
Hu MI, Hoff AO, Toth BB, Altundag K, Johnson M, Warneke C, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Hortobagyi GN, Gagel RF. Osteonecrosis of the jaw: long-term follow-up shows variable rate of healing. J Clin Oncology 25(18S):9061, 2007. e-Pub 2007.
Hu MI, Hoff AO, Gagel RF. Short-term use of teriparatide in the treatment of postoperative hypocalcemia (#M429). Journal of Bone and Mineral Research 21(Suppl 1):S438, 2006. e-Pub 2006.
Hu MI, Waguespack SG, Sarlis NJ. Unusually intense breast uptake of radioiodine in a non-lactating woman (#20). Thyroid 16(9):863-4, 2006. e-Pub 2006.

Book Chapters

Santillan, MR, Dadu, R, Gagel, RF, Grubbs, EG, Hu, MI. Systemic Therapies for Advanced Medullary Thyroid Carcinoma, 293-307, 2025.
Hu MI, Santillan, Dadu, Gagel, Grubbs. Systemic Therapies for Advanced Medullary Thyroid Carcinoma. Springer Nature, 2024.
Rich TA, Hu MI, Martin JW, Perrier ND, Waguespack SG. CDC73-related disorders. In: GeneReviews at GeneTests, 2023.
Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. In: Curr Opin Endocrinol Diabetes Obes. 10th. McGraw-Hill, 744-65, 2021.
Lee M, Waguespack SG, Graham PH, Hu MI, Zafereo ME. Syndromic Medullary Thyroid Carcinoma: MEN 2A and MEN 2B. In: Surgical and Medical Management of Diseases of the Thyroid and Parathyroid. Plural Publishing, Inc, 371-390, 2020.
Dadu R, Hu MI. Medical Treatment Decision-Making for Advanced Medullary Thyroid Cancer. In: Thyroid Cancer: A Case-Based Approach. 2nd. Springer Nature, 2020.
Hu MI, Grubbs EG, Sosa JA. Medullary Thyroid Carcinoma. In: Medical Management of Thyroid Disease. 3rd. CRC Press, 225-42, 2019.
Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. CDC73-Related Disorders. In: GeneReviews. GeneReviews, 2018.
Callejas LP, Ahn P, Holsinger FC, Hu MI. Thyroid and Parathyroid Cancers. In: Cancer Management Handbook. 17th. UBM Medica US, 2016.
Hu, MI, Jimenez, C, Busaidy, NL, Habra, MA. Endocrinologic issues, 343-360, 2015.
Dadu R, Gagel RF, Hu MI. Medical treatment decision-making for advanced, progressive medullary thyroid cancer. In: Thyroid Cancer: A Case-Based Textbook. Springer, 365-374, 2015.
Jackson MA, Rich TA, Hu MI, Perrier ND, Waguespack SG. CDC73-related disorders. In: GeneReview, 2015.
Hu MI, Jimenez C, Busaidy NL, Habra M. Long-term and late endocrine effects of cancer survivorship. In: Cancer Survivorship. 1st. Springer, 2014.
Waguespack SG, Grubbs EG, Hu MI. Multiple endocrine neoplasia type 2. In: Clinical Genomics: Practical Applications in Adult Patient Care. 1st. McGraw Hill Education, 278-83, 2014.
Dadu R, Ahn P, Holsinger FC, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 16th. UBM Medica, 2014.
Dadu R, Ahn P, Holsinger FC, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 15th. UBM Medica, 2013.
Hu MI, Jimenez C, Cote GJ, Gagel RF. Medullary thyroid carcinoma. In: The Thyroid. 10th. Lippincott Williams & Wilkins, 744-65, 2012.
Thosani S, Ahn P, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 14th. CMP Medica, 2012.
Alford E, Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 13th Edition. CMPMedica, 2011.
Hu, MI, Gagel, RF. Multiple Endocrine Neoplasia Type 2, 2742-2758, 2010.
Hu M, Gagel RF. Multiple endocrine neoplasia type 2. In: Endocrinology. 6th edition. Saunders, 2010.
Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 12th Edition. CMPMedica, 51-70, 2010.
Hu, MI, Sherman, SI. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery, 2nd edition, 85-103, 2009.
Hu MI, Yeung SJ, Gagel RF. Endocrine paraneoplastic syndromes. In: Internal Medicine Care of Cancer Patients. BC Decker Inc; the Holland-Frei Series, 2009.
Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont J. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 11th Edition. CMPMedica, 2009.
Hu MI, Gagel RF. Calcitonin gene family of peptides. In: Principles of Bone Biology, 3rd edition, 2008.
Fournier I, Hu MI, Waguespack S, Grubbs EG, Zafereo ME. Medullary Thyroid Carcinoma. 2nd. Publishing House.

Letters to the Editor

Matrone, A, Kroiss, M, Gild, ML, Hamidi, S, Sayehli, CM, Siddal, R, Gambale, C, Prete, A, Hu, MI, Robinson, BG, Elisei, R. Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer. Thyroid 34: 1177-1180, 2024.
Maniakas, A, Hu, MI, Gunn, GB, Zafereo, M. Reply to Letter to the Editor regarding “Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer”. Head and Neck 46: 1848-1849, 2024.
Sarvestani, AL, Lambdin, J, Hu, MI, Cabanillas, ME, Waguespack, SG, Hernandez, J, Zafereo, M. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Annals of surgical oncology 31: 2202-2203, 2024.
Gouda, MA, Hu, MI, Cabanillas, ME, Wu, J, Meric-Bernstam, F, Subbiah, V. Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors. Annals of Oncology 34: 946-948, 2023.
Alsharif O, Panella T, Nodit L, Hu MI. ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma. Thyroid 33: 774-776, 2023.
Hu, MI. Response letter to the editor. Journal of Clinical Endocrinology and Metabolism 100: L7, 2015.